EYE nova eye medical limited

EYE Summary (August 2024): Incredibly Undervalued, page-8

  1. 15,034 Posts.
    lightbulb Created with Sketch. 1686

    Apologies, I found the full year 2023 stuff which has not been posted here in HC, other stuff is missing too, which is strange:


    In 2022 EYE had revenues (sales/gross income) of $13.378 mil and a net loss of $7.817 - expenses of $21.195 mil.

    In 2023 EYE had revenue of $17 mil and a loss of $17 mil, so expenses of $34 mil, of which there was $6.044 mil recorded as a one off impairment, obviously with normalised expenses of $28 mil.

    In 2024 income has been $23.5 mil, so it remains to be seen how much expenses have risen. They are expected to have risen substantially and there will be a significant loss.

    *The impairment item was due to the inability of the AlphaRET segment to generate independent cashflows, requiring a cash investment of $6.044 mil, more than the company has available. Not quite a one off non cash item as characterised by TheAnalyst007
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
13.5¢
Change
0.010(8.00%)
Mkt cap ! $38.35M
Open High Low Value Volume
13.5¢ 14.5¢ 13.0¢ $271.5K 1.986M

Buyers (Bids)

No. Vol. Price($)
6 206547 13.0¢
 

Sellers (Offers)

Price($) Vol. No.
13.5¢ 2538 2
View Market Depth
Last trade - 12.34pm 08/07/2025 (20 minute delay) ?
EYE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.